Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 4
1964 10
1965 5
1966 4
1967 7
1968 16
1969 12
1970 15
1971 15
1972 15
1973 13
1974 15
1975 18
1976 24
1977 15
1978 19
1979 25
1980 24
1981 22
1982 20
1983 28
1984 19
1985 20
1986 23
1987 22
1988 43
1989 46
1990 53
1991 36
1992 42
1993 50
1994 59
1995 38
1996 44
1997 66
1998 65
1999 65
2000 66
2001 57
2002 42
2003 52
2004 62
2005 68
2006 50
2007 57
2008 76
2009 57
2010 76
2011 68
2012 70
2013 95
2014 85
2015 62
2016 62
2017 81
2018 115
2019 111
2020 104
2021 121
2022 121
2023 104
2024 58

Text availability

Article attribute

Article type

Publication date

Search Results

2,756 results

Results by year

Filters applied: . Clear all
Page 1
Myasthenia gravis. Update on diagnosis and therapy.
García Estévez DA, Pardo Fernández J. García Estévez DA, et al. Med Clin (Barc). 2023 Aug 11;161(3):119-127. doi: 10.1016/j.medcli.2023.04.006. Epub 2023 May 27. Med Clin (Barc). 2023. PMID: 37248131 Review. English, Spanish.
Myasthenia gravis is an autoimmune disease caused by the presence of specific antibodies targeting different postsynaptic components of the neuromuscular junction, and is clinically characterized by the presence of fatigueable muscle weakness. ...In addition, in rec …
Myasthenia gravis is an autoimmune disease caused by the presence of specific antibodies targeting different postsynaptic comp …
Myasthenia gravis: subgroup classification and therapeutic strategies.
Gilhus NE, Verschuuren JJ. Gilhus NE, et al. Lancet Neurol. 2015 Oct;14(10):1023-36. doi: 10.1016/S1474-4422(15)00145-3. Lancet Neurol. 2015. PMID: 26376969 Review.
Patients with myasthenia gravis should be classified into subgroups to help with therapeutic decisions and prognosis. Subgroups based on serum antibodies and clinical features include early-onset, late-onset, thymoma, MUSK, LRP4, antibody-negative, and ocular forms …
Patients with myasthenia gravis should be classified into subgroups to help with therapeutic decisions and prognosis. Subgroup …
Ocular myasthenia gravis: a review and practical guide for clinicians.
Shuey NH. Shuey NH. Clin Exp Optom. 2022 Mar;105(2):205-213. doi: 10.1080/08164622.2022.2029683. Epub 2022 Feb 14. Clin Exp Optom. 2022. PMID: 35157811 Free article. Review.
Myasthenia gravis is a rare autoimmune disease characterised by autoantibodies preventing normal function of acetylcholine receptors at the post-synaptic membrane of the neuromuscular junction. ...The goals of management are to alleviate symptoms, and where possible …
Myasthenia gravis is a rare autoimmune disease characterised by autoantibodies preventing normal function of acetylcholine rec …
Treatment of Myasthenia Gravis.
Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ. Farmakidis C, et al. Neurol Clin. 2018 May;36(2):311-337. doi: 10.1016/j.ncl.2018.01.011. Neurol Clin. 2018. PMID: 29655452 Free PMC article. Review.
With specialized care, patients with myasthenia gravis can have very good outcomes. The mainstays of treatment are acetylcholinesterase inhibitors, and immunosuppressive and immunomodulatory therapies. ...The 2 exceptions are acetylcholinesterase inhibitors and comp …
With specialized care, patients with myasthenia gravis can have very good outcomes. The mainstays of treatment are acetylcholi …
Myasthenia gravis in clinical practice.
Estephan EP, Baima JPS, Zambon AA. Estephan EP, et al. Arq Neuropsiquiatr. 2022 May;80(5 Suppl 1):257-265. doi: 10.1590/0004-282X-ANP-2022-S105. Arq Neuropsiquiatr. 2022. PMID: 35976295 Free PMC article. Review.
BACKGROUND: Myasthenia gravis is largely a treatable disease, but it can result in significant morbidity and even mortality, which can usually be avoided, or at least mitigated, with timely diagnosis and appropriate treatment of the disease. ...METHODS: The authors …
BACKGROUND: Myasthenia gravis is largely a treatable disease, but it can result in significant morbidity and even mortality, w …
The epidemiology of myasthenia gravis.
Bubuioc AM, Kudebayeva A, Turuspekova S, Lisnic V, Leone MA. Bubuioc AM, et al. J Med Life. 2021 Jan-Mar;14(1):7-16. doi: 10.25122/jml-2020-0145. J Med Life. 2021. PMID: 33767779 Free PMC article. Review.
Neuromuscular junction (NMJ) disorders include several dysfunctions that ultimately lead to muscle weakness. Myasthenia gravis (MG) is the most prevalent NMJ disorder with a highly polymorphic clinical presentation and many different faces. ...
Neuromuscular junction (NMJ) disorders include several dysfunctions that ultimately lead to muscle weakness. Myasthenia gravis …
Myasthenia gravis: an update for the clinician.
Sieb JP. Sieb JP. Clin Exp Immunol. 2014 Mar;175(3):408-18. doi: 10.1111/cei.12217. Clin Exp Immunol. 2014. PMID: 24117026 Free PMC article. Review.
This paper provides a thorough overview of the current advances in diagnosis and therapy of myasthenia gravis (MG). Nowadays the term 'myasthenia gravis' includes heterogeneous autoimmune diseases, with a postsynaptic defect of neuromuscular transmissi …
This paper provides a thorough overview of the current advances in diagnosis and therapy of myasthenia gravis (MG). Nowadays t …
Myasthenia Gravis.
Gilhus NE. Gilhus NE. N Engl J Med. 2016 Dec 29;375(26):2570-2581. doi: 10.1056/NEJMra1602678. N Engl J Med. 2016. PMID: 28029925 Review. No abstract available.
Ocular myasthenia gravis: a review.
Nair AG, Patil-Chhablani P, Venkatramani DV, Gandhi RA. Nair AG, et al. Indian J Ophthalmol. 2014 Oct;62(10):985-91. doi: 10.4103/0301-4738.145987. Indian J Ophthalmol. 2014. PMID: 25449931 Free PMC article. Review.
Myasthenia gravis (MG) is a disease that affects the neuro-muscular junction resulting in classical symptoms of variable muscle weakness and fatigability. ...Very often, a patient of MG may present to the ophthalmologist given that a large proportion of patients wit …
Myasthenia gravis (MG) is a disease that affects the neuro-muscular junction resulting in classical symptoms of variable muscl …
Myasthenia gravis: Frequently asked questions.
Morren JA, Li Y. Morren JA, et al. Cleve Clin J Med. 2023 Feb 1;90(2):103-113. doi: 10.3949/ccjm.90a.22017. Cleve Clin J Med. 2023. PMID: 36724914 Free article. Review.
Myasthenia gravis is a disorder of neuromuscular junction transmission, the result of antibodies against the post-synaptic aspect of the neuromuscular junction. ...This review uses a question-and-answer format to provide up-to-date, high-yield, clinically relevant i …
Myasthenia gravis is a disorder of neuromuscular junction transmission, the result of antibodies against the post-synaptic asp …
2,756 results